Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Applying Current Evidence on Tailored Therapeutic Strategies to Improve Outcomes for Patients With Myeloproliferative Neoplasms
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: April 21, 2022 Expiration: April 20, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Geron Corporation
Incyte Corporation
Sumitomo Dainippon Pharma Oncology, Inc.
Prithviraj Bose, MD
Stephen Oh, MD, PhD
Brady L. Stein, MD, MHS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Navigate safety and efficacy data for emerging treatment options and novel formulations used in the management of MPNs
  • Develop individualized treatment plans for patients with MPNs based on risk stratification and symptom burden
  • Plan management strategies for patients with MF with anemia and/or thrombocytopenia
  • Discuss the most recent scientific findings and how this novel information will continue to shape the clinical landscape in the future

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has disclosed that he has received consulting fees from AbbVie, Blueprint, Bristol-Myers Squibb, CTI Biopharma, Incyte, Karyopharm, Novartis, PharmaEssentia, and Sierra and funds for research support from Astellas, Blueprint, Bristol-Myers Squibb, Cogent, Constellation, CTI Biopharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior.
Stephen Oh, MD, PhD

Assistant Professor
Division of Hematology
Department of Medicine
Washington University School of Medicine
St Louis, MO

Stephen Oh, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Blueprint, Bristol-Myers Squibb, Constellation, CTI Biopharma, Disc, Geron, Incyte, PharmaEssentia, and Sierra.
Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has disclosed that he has received consulting fees from Constellation and PharmaEssentia.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer had individual publicly traded stocks/stock options in AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other HCPs who care for patients with MPNs, including ET, PV, and MF.

Goal

The goal of this activity is to improve the knowledge and competence of learners in treating patients with myeloproliferative neoplasms.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 21, 2022, through April 20, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Applying Current Evidence on Tailored Therapeutic Strategies to Improve Outcomes for Patients With Myeloproliferative Neoplasms
  • CME

Loading...
In this on-demand webcast capturing a live CCO symposium, experts review best practices and emerging strategies for managing patients with myeloproliferative neoplasms, including essential thrombocythemia, myelofibrosis, and polycythemia vera.
Prithviraj Bose, MD
Stephen Oh, MD, PhD
Brady L. Stein, MD, MHS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: April 21, 2022 Expiration: April 20, 2023

Related Content

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Adolfo de la Fuente Burguera, MD
Program Director
Claudio Cerchione, MD, PhD Naval G. Daver, MD person default Pau Montesinos, MD, PhD Eytan M. Stein, MD
Released: December 1, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director
Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE person default Giovanni Martinelli, MD
Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)

Released: November 29, 2022

On-demand webcast from a CAP satellite symposium on the role of pathology in myelodysplastic syndromes, from Clinical Care Options (CCO)

Tal Oren, MD, PhD Alexa J. Siddon, MD Cecilia Yeung, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point ABPath MOC: maximum of 1.0 Lifelong Learning point Released: November 29, 2022 Expired: November 28, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Geron Corporation
Incyte Corporation
Sumitomo Dainippon Pharma Oncology, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings